The Scientist - Human Ebola vaccine trial begins

AI Thread Summary
The Phase I safety trial for a new Ebola vaccine, which began on November 18, will assess the vaccine's DNA component over a year. Developed by the Vaccine Research Center at NIAID, the vaccine combines naked DNA and an adenoviral vector. The trial involves 27 participants, with 21 receiving the vaccine and 6 a placebo, administering escalating doses of plasmid DNA encoding Ebola proteins through a needle-less injection. Initial reports indicate that only two subjects have received injections so far. The discussion also touches on the perception of Ebola as a deadly virus, noting that while some strains have high mortality rates, the portrayal of Ebola in media may exaggerate its lethality compared to other diseases like HIV.
iansmith
Staff Emeritus
Science Advisor
Gold Member
Messages
1,320
Reaction score
2
Phase I safety test of the multimodal vaccine's DNA component will last 1 year | By Jeffrey M Perkel


The leader of the team that designed an Ebola vaccine and tested it in macaque monkeys expects to see no adverse effects in the human trial of the vaccine, which began last Tuesday (November 18). The phase I trial just initiated will test the vaccine's DNA component, manufactured by Vical Inc., a San Diego–based biotech company. The entire vaccine, developed by Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, employs both naked DNA and an adenoviral vector.

The trial will include 27 subjects, 21 of whom will receive the vaccine and six of whom will receive a placebo. At monthly intervals, subjects will receive an escalating dose (2 mg, 4 mg, 8 mg) of naked plasmid DNA—grown in bacteria—encoding Ebola nucleoprotein, the Zaire-subtype glycoprotein, and the Sudan-subtype glycoprotein, in phosphate-buffered saline, delivered via pressure injection into muscle, in a needle-less process. As of last Friday, only two subjects had received injections, according to VRC Director Gary Nabel, who designed and tested the vaccine.

http://www.biomedcentral.com/news/20031124/06
 
Last edited by a moderator:
Biology news on Phys.org
Is Ebola really that much of a killer to warrant a vaccine? Or is it just the fact that it is seen as THE killer virus from the movies which liquifies your organs, rather than something as boring as HIV..
 
Originally posted by Jikx
Is Ebola really that much of a killer to warrant a vaccine? Or is it just the fact that it is seen as THE killer virus from the movies which liquifies your organs, rather than something as boring as HIV..

Yes, Ebola is an hemorrhagic fever but liquification of the organs is rarely seems. Some strains of the virus have an 90% killing rate whereas some other strain have a less than 10% killing rate. Central african countries have sporadic outbreaks killing couple of people.
 
Chagas disease, long considered only a threat abroad, is established in California and the Southern U.S. According to articles in the Los Angeles Times, "Chagas disease, long considered only a threat abroad, is established in California and the Southern U.S.", and "Kissing bugs bring deadly disease to California". LA Times requires a subscription. Related article -...
I am reading Nicholas Wade's book A Troublesome Inheritance. Please let's not make this thread a critique about the merits or demerits of the book. This thread is my attempt to understanding the evidence that Natural Selection in the human genome was recent and regional. On Page 103 of A Troublesome Inheritance, Wade writes the following: "The regional nature of selection was first made evident in a genomewide scan undertaken by Jonathan Pritchard, a population geneticist at the...

Similar threads

Back
Top